GRAL News and Press, GRAIL Inc. From 02/20/26

2026-02-20 14:13:10 ET This isn't a good day for investors in Grail (NASDAQ: GRAL) . The stock declined more than 50% by 1:30 p.m. today. The move comes on the day of its fourth-quarter earnings results, but more importantly, the release of its top-line results from a major trial ...

2026-02-20 13:25:16 ET More on Hims & Hers Health, GRAIL, Inc. GRAIL, Inc. (GRAL) Q4 2025 Earnings Call Transcript What Is HIMS Worth Without GLP-1? Earnings Preview Hims & Hers Health: 5 Key Questions Ahead Of Critical Q4 Earnings Grail slides as tri...

2026-02-20 07:04:03 ET from Canaccord Genuity issued a price target of $80.00 for GRAL on 2026-02-20 11:49:59. The adjusted price target was set to $80.00. At the time of the announcement, GRAL was trading at $101.53. The overall price target consensus is at $102.60 with...

2026-02-20 05:58:10 ET More on GRAIL, Inc. GRAIL, Inc. (GRAL) Q4 2025 Earnings Call Transcript GRAIL Inc. - Illumina's Divested Holy Grail GRAIL, Inc. (GRAL) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Grail slides as trial misses pr...

2026-02-20 05:07:49 ET Stock futures were higher Friday morning as investors positioned ahead of key economic releases, including the Q4 GDP advance estimate and December PCE inflation data due at 8:30 AM ET.... Read the full article on Seeking Alpha For further details see: ...

2026-02-20 04:41:36 ET Read the full article on Seeking Alpha For further details see: Grail slides as trial misses primary endpoint, fails to show significant stage III-IV cancer reduction

Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Grail, Inc. (NASDAQ: GRAL). The investigation focuses on Grail’s executive officers and whether investor losses may be recovered under federal securities laws. What if I purchased Grail securities? ...

2026-02-19 21:25:39 ET More on GRAIL, Inc. GRAIL, Inc. (GRAL) Q4 2025 Earnings Call Transcript GRAIL Inc. - Illumina's Divested Holy Grail GRAIL, Inc. (GRAL) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow GRAIL, Inc. Q4 2025 Earnings Pr...

2026-02-19 21:25:00 ET GRAIL, Inc. (GRAL) Q4 2025 Earnings Call February 19, 2026 5:00 PM EST Company Participants Robert Ragusa - CEO & Director Harpal Kumar - Chief Scientific Officer & President International Joshua Ofman - President Aaron Freidin ...

GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results PR Newswire Sold More Than 185,000 Galleri® Tests in 2025, Growing U.S. Galleri Revenue 26% Year-Over-Year to $136.8  Million Completed Galleri PMA Submission to FDA Shared Topline Results from ...